Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes.
J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering.
The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing.
A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorgan.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Contact:
Christi WaarichSenior Director, Investor Relationschristi.waarich@cogentbio.com617-830-1653

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
22 minutes ago
- Business Insider
Hub Group (HUBG) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst J. Bruce Chan maintained a Buy rating on Hub Group today and set a price target of $46.00. The company's shares closed today at $35.92. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bruce Chan covers the Industrials sector, focusing on stocks such as Forward Air, Hub Group, and GXO Logistics. According to TipRanks, Bruce Chan has an average return of 0.4% and a 49.79% success rate on recommended stocks. In addition to Stifel Nicolaus, Hub Group also received a Buy from Deutsche Bank 's Richa Harnain in a report issued today. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Hub Group (NASDAQ: HUBG).
Yahoo
40 minutes ago
- Yahoo
CSX profits fall on lower revenue, higher costs
CSX's second-quarter profits slumped as unfavorable changes in traffic mix drove a revenue decline and costs rose amid congestion and detours related to a pair of main line outages. But executives said they were encouraged by the pace of the railroad's (NASDAQ: CSX) operational recovery during the quarter, which produced improvements in on-time performance. 'We are proud of how our network performance has bounced back from the challenges of the first quarter,' Chief Executive Joe Hinrichs told investors and analysts on the railroad's earnings call Wednesday. The railroad's operating income declined 11%, to $1.28 billion, as revenue decreased 3%, to $3.57 billion. Earnings per share declined 10%, to 44 cents. CSX's operating ratio, including its trucking operations, was 64.1, a 3.2-point increase from a year ago as expenses rose 2%. Overall quarterly volume was flat. Intermodal was up 2%, merchandise declined 2%, and coal volume increased 1%. International intermodal volume grew during the quarter, while domestic volume was stable. In the merchandise segment, growth in metals, minerals, and agricultural shipments were not enough to offset declines in automotive, forest products, chemicals, and fertilizer traffic. 'Many of the industrial markets we serve continue to face challenges with uncertainty around tariffs, trade, interest rates, and the overall direction of the economy,' Chief Commercial Officer Kevin Boone said. CSX still expects overall volume growth this year thanks to dozens of industrial development projects coming on line and conversion of freight from highway to intermodal, Boone said. CSX also is encouraged by the progress of its new Southeast Mexico Express interline intermodal service launched with Canadian Pacific Kansas City in December via their new interchange at Myrtlewood, Ala., on the former Meridian & Bigbee short line. The Howard Street Tunnel clearance project remains on schedule toward completion early in the fourth quarter, while related bridge clearance work in Baltimore is on pace for completion in the second quarter of 2026. The tunnel will reopen when work is complete, allowing CSX to end daily detours around Baltimore. The tunnel and bridge clearance work will open up the carrier's I-95 corridor for double-stack intermodal service for the first time and allow Baltimore-Midwest stack traffic to take the direct route via the former Baltimore & Ohio main line, rather than the current roundabout routing via Selkirk, N.Y., on the former New York Central Water Level Route. Work to reopen the hurricane-damaged Blue Ridge Subdivision – the former Clinchfield Railroad in rugged western North Carolina and eastern Tennessee – is expected to be completed on schedule in the fourth quarter, as well. 'We are very pleased with the progress that has been made at our Howard Street Tunnel and Blue Ridge rebuild projects. We expect completion in the fourth quarter, which will remove two key constraints from our network,' Hinrichs said. 'Finishing these two projects will open back up two of our four north-south routes, and … we're excited about removing the last impediment to double stack intermodal on the I-95 corridor.' A string of harsh weather, combined with the main line outages, led to congestion after the Feb. 1 shutdown of the Howard Street Tunnel. CSX's operations accelerated as the quarter went on, with average train speed increasing 8% from April through June and dwell declining by 18%. The number of cars online — a key congestion metric — declined 10% as the quarter progressed. 'Our recovery is a true testament to the hard work and dedication of every railroader at CSX,' Chief Operating Officer Mike Cory said. Intermodal trip-plan compliance held steady at 90% compared to the first quarter but was down 4 points compared to a year ago. Merchandise trip-plan compliance of 75% was 6 points higher than the first quarter but 5 points lower than a year ago. Customer switch data of 94% was flat compared to last year's second quarter and a 1-point improvement over the first quarter. The on-time performance figures are not yet where CSX wants them, Cory says, but he expects ongoing improvement, particularly after the Howard Street and Blue Ridge projects wrap up and allow the railroad to end the related detours of up to 22 trains per day. 'While these projects unlock significant capacity for the entire network, we are also upgrading our capacity and throughput at our yard in Indianapolis, with the extension of the hump pullback,' Cory said of Avon Yard in Indiana, one of five hump yards on the system. 'While this project is small in nature relative to the other two, it'll give us the ability to hump more cars … at a very critical yard in our network.' Despite the service issues, CSX's customers gave the railroad the highest marks ever in a second-quarter internal survey, Boone said. And Hinrichs added regulators received zero complaints from shippers despite the impact of congestion. Subscribe to FreightWaves' Rail e-newsletter and get the latest insights on rail freight right in your look: Weaker coal, carloads hit CSX earnings As merger talk heats up, deep bench will advise rail regulator Analysis: What a Union Pacific – Norfolk Southern merger would look like BNSF aims to grow carload traffic with rail service upgrades The post CSX profits fall on lower revenue, higher costs appeared first on FreightWaves. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SentinelOne (S) Rallies 9.8% on $10-Billion Potential Buyout
We recently published . SentinelOne, Inc. (NYSE:S) is one of Monday's biggest gainers. SentinelOne saw its share prices increase by 9.83 percent on Monday to close at $19.78 apiece following reports that it was mulling over a sale to Palo Alto Networks Inc. (NASDAQ:PANW). According to the reports, SentinelOne, Inc. (NYSE:S) and Palo Alto Networks Inc. (NASDAQ:PANW) are now in advanced discussions for the potential merger, which could be valued between $8 billion and $10 billion. Palo Alto, founded by Israeli entrepreneur Nir Zuk, is one of the largest cybersecurity companies globally with a market capitalization of $134 billion. Both firms have yet to issue their comments about the rumors. The acquisition reports followed SentinelOne, Inc.'s (NYSE:S) disappointing earnings performance in the first quarter of fiscal year 2026. A cybersecurity expert monitoring the security of the company's assets, emphasizing the importance of data protection. According to the company, its net loss nearly tripled to $208 million from $70 million in the same period last year, despite revenues increasing by 23 percent to $229 million from $186 million year-on-year. Looking ahead, SentinelOne, Inc. (NYSE:S) expects $242 million in revenues for the second quarter of the fiscal year, as well as between $996 million and $1 billion for the full fiscal year. While we acknowledge the potential of S as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data